Sabine Brookman-May joins Aura Biosciences as Therapeutic Area Head, Urologic Oncology

Sabine D. Brookman-May is the Vice President of Bladder Cancer Development, Research and Development at Janssen Pharmaceutical Companies of Johnson & Johnson. She also serves as a professor of Urology at Ludwig Maximilian University of Munich, specializing in Urology, Oncology, and Sports and Exercise Medicine.

Sabine also serves as the Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences.

In connection to her new retirement, Sabine Brookman-May shared a post by Aura Biosciences on X, adding:

“I am very excited to join the leadership of Aura Biosciences as Therapeutic Area Head, Urologic Oncology and keep on contributing to Bladder Cancer research and new therapies in oncology. Looking forward to a continuous collaboration across the Urology and GU-Oncology community!”

Quoting Aura Biosciences post:

“We are thrilled to welcome Sabine Brookman-May, MD, FEBU, as our SVP, Therapeutic Area Head Urologic Oncology!”

Aura Biosciences is a biotechnology company focused on developing innovative therapies for cancer. Their approach often centers on targeted therapies that utilize a unique technology platform involving virus-like particles (VLPs). These VLPs can be designed to deliver therapeutic agents specifically to cancer cells while sparing healthy tissue, aiming to improve treatment efficacy and reduce side effects.

The company has been involved in clinical trials for various cancer treatments, particularly in the field of ocular oncology, such as uveal melanoma. Aura Biosciences emphasizes the importance of precision medicine and aims to harness the body’s immune response in their therapeutic strategies.

Find out more on OncoDaily.